MarketPulse

Phase 2b trial

2 articles
BenzingaBenzinga··Business Wire

Nektar Therapeutics Faces Securities Fraud Investigation After Failed Trial Announcement

Law firm investigates $NKTR over December trial failure disclosure. Stock dropped 7.8% after alopecia areata Phase 2b study missed endpoints due to ineligible patients.
NKTRshareholder lawsuitstock price decline
GlobeNewswire Inc.GlobeNewswire Inc.··Bernstein Liebhard Llp

Nektar Therapeutics Faces Securities Class Action Over Failed Trial Disclosures

Law firm Bernstein Liebhard announces class action against $NKTR over alleged misrepresentations regarding Phase 2b trial results, affecting investors from February to December 2025.
PLUGSLNONKTRsecurities fraudclass action lawsuit